【摘要】：目的觀察早期使用β受體阻滯劑對全身炎癥反應(yīng)綜合征(SIRS)患者預(yù)后的影響。方法選擇2011年1—12月北京大學(xué)人民醫(yī)院重癥監(jiān)護(hù)病房收治的患者72例,根據(jù)患者的臨床表現(xiàn)判斷其有無SIRS,并根據(jù)治療方案將患者分為治療組41例,對照組31例。治療組在入院后48 h內(nèi)使用β受體阻滯劑,而對照組不使用β受體阻滯劑,觀察兩組患者在入院時和入院第3、7天APACHEⅡ評分、尿量和病死率等結(jié)果。結(jié)果兩組患者在入院時和入院第3天APACHEⅡ評分差異無統(tǒng)計(jì)學(xué)意義(P值分別為0.945和0.124),在第7天時,治療組的評分顯著低于對照組(P=0.001)。兩組入院時和入院第3天尿量/入量比值差異無統(tǒng)計(jì)學(xué)意義(P值分別為0.086和0.067),入院第7天治療組尿量/入量比值顯著高于對照組(P=0.006)。住院期間治療組病死率明顯低于對照組(P=0.001)。結(jié)論SIRS患者早期給予β受體阻滯劑可在入院第7天明顯降低APACHEⅡ評分,改善患者癥狀,改善患者預(yù)后,降低病死率;而且在維持正常血壓的前提下,不影響重要器官的灌注。
[Abstract]:Objective to observe the effect of early use of 尾-blocker on the prognosis of patients with systemic inflammatory response syndrome (Sirs). Methods A total of 72 patients in intensive care unit of Peking University people's Hospital from January to December 2011 were selected. According to the clinical manifestations of the patients, the patients were divided into treatment group (n = 41) and control group (n = 31). The patients in the treatment group were treated with 尾 -blocker within 48 hours after admission, while the control group was not treated with the 尾 -blocker. The Apache 鈪，

本文編號：2123091